Jefferies estimates a 59% probability that AstraZeneca's kidney drug zibotentan will succeed in the phase 3 ZENITH-HP trial, with results expected in the first half of 2027. The trial tests zibotentan combined with Farxiga in patients with high protein levels in urine, aiming to slow kidney decline. Jefferies models potential sales of $1.3 billion by 2034 if successful, higher than consensus estimates. AstraZeneca's stock is rated 'buy' with a 41% upside target, as cardiovascular trial results in 2027 could further boost confidence in the company's pipeline.
AstraZeneca trades at USD 166.59 on Pluang as of Oct 20, 2026 20:21 WIB, showing a 1.61% gain in one day. The stock's market cap stands at $256.44 billion, with strong buy interest at 87% of orders. Typical holding time for AZN on Pluang is 126 days, reflecting steady investor confidence.
